๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

โœ Scribed by John M. Kovarik; Robert Schmouder; Denise Barilla; Yibin Wang; Gerolf Kraus

Book ID
108640081
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
117 KB
Volume
57
Category
Article
ISSN
0306-5251

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Single and multiple dose pharmacokinetic
Single and multiple dose pharmacokinetics of etizolam in healthy subjects
โœ C. Fracasso; S. Confalonieri; S. Garattini; S. Caccia ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer ๐ŸŒ English โš– 498 KB

The pharmacokinetics of etizolam, a new thienodiazepine derivative, has been examined after single and multiple (0.5 mg tablet) (0.5 mg b.d for 1 week) oral therapeutic doses in healthy volunteers. The single-dose kinetic profile of etizolam suggested that absorption after oral dosage was reasonably

Single intravenous dose and steady-state
Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects
โœ John G. Wagner; Teck L. Ling; Edward J. Mroszczak; Donna Freedman; Ann Wu; Bee H ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 617 KB

Nicardipine HCI oral doses (10-40 mg) were administered sequentially to six healthy subjects. For each regimen the capsule dose was administered every 8 hours (q 8 h) for 3 days and the plasma profiles of nicardipine and its pyridine analogue (M5) were determined following the last dose on day 4. St

THE EFFECT OF FOOD ON THE PHARMACOKINETI
THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF MULTIPLE-DOSE TERBINAFINE IN YOUNG AND ELDERLY HEALTHY SUBJECTS
โœ JERRY NEDELMAN; JEFFREY A. CRAMER; BRUCE ROBBINS; EKATERINA GIBIANSKY; CHENG-TAO ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 669 KB

Pharmacokinetic (PK) parameters for terbinaยฎne were assessed in 15 elderly and 15 young healthy subjects randomized to receive 250 mg Lamisil 1 once daily for 15 d in a two-period, two-treatment, two-sequence, crossover (fed versus fasted) design within age groups. On each treatment day except days